Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company’s portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company’s web site at www.alteon.com.
- 17 years ago
QualityStocks
Synvista Therapeutics, Inc. (AMEX: SYI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Launches 12-Month AI-Driven Marketing Campaign With AGORACOM
LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced a 12-month online marketing campaign with…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Strengthens Balance Sheet with Full Conversion of $13.3 Million Notes
Datavault AI (NASDAQ: DVLT), a pioneer in AI-driven data monetization, announced the full conversion of…
-
Nightfood Holdings Inc. (NGTF) Offering a Portfolio of AI-Powered Robots Designed to Streamline Operations and Enhance Efficiency
Nightfood Holdings has a lineup of AI-powered robots to streamline operations across industries, weaving technology…